Financial Results - Standalone (Quarter ended 30th June 2026)

  • Revenue from Operations: ₹20,696.49 lakhs (Q1 FY26: ₹19,604.71 lakhs)
  • Other Income: ₹174.44 lakhs (Q1 FY26: ₹59.31 lakhs)
  • Total Income: ₹20,870.93 lakhs (Q1 FY26: ₹19,664.02 lakhs)
  • Profit Before Tax: ₹2,814.42 lakhs (Q1 FY26: ₹2,386.18 lakhs)
  • Tax Expense: ₹701.16 lakhs (Current Tax: ₹610.00 lakhs, Deferred Tax: ₹91.16 lakhs)
  • Net Profit After Tax: ₹2,113.26 lakhs (Q1 FY26: ₹1,820.75 lakhs)
  • Earnings Per Share (Basic/Diluted): ₹2.26 (Q1 FY26: ₹2.05)
  • Paid-up Equity Share Capital: ₹936.52 lakhs (Face Value: Re.1 each)

Financial Results - Consolidated (Quarter ended 30th June 2026)

  • Revenue from Operations: ₹20,696.49 lakhs
  • Other Income: ₹174.44 lakhs
  • Total Income: ₹20,870.93 lakhs
  • Profit Before Tax: ₹2,720.50 lakhs
  • Tax Expense: ₹700.40 lakhs (Current Tax: ₹610.00 lakhs, Deferred Tax: ₹90.40 lakhs)
  • Net Profit After Tax: ₹2,020.10 lakhs
  • Share of Profit in Associate (VKT Pharma): ₹70.80 lakhs
  • Total Comprehensive Income: ₹2,084.40 lakhs
  • Earnings Per Share (Basic/Diluted): ₹2.23

Annual General Meeting Details

  • 38th AGM Date: Wednesday, 23rd September 2026 (to be held through Video Conference/Audio-Visual Means)
  • Book Closure Period: Thursday, 17th September 2026 to Wednesday, 23rd September 2026 (both days inclusive)
  • Record Date for Dividend: Wednesday, 16th September 2026 (for determining eligibility for dividend for FY 2025-26, if approved at AGM)
  • Dividend payment will be made within stipulated time period if approved

Management Reappointment

  • Reappointment: Mr. Ramesh Babu Potluri (DIN:00166381) as Chairman and Managing Director
  • Term: 5 years from 1st October 2026 to 30th September 2031
  • Status: Promoter and Executive Director, liable to retire by rotation
  • Approval Required: Subject to shareholder approval at ensuing AGM
  • Background: Mr. Potluri is a Post-Graduate Technocrat with over four decades of experience in pharmaceutical industry, particularly in R&D, process innovation, manufacturing, and business leadership. He acquired SMS Pharmaceuticals in 1990 when it was a sick company and led its turnaround.
  • Relationships: His sons Mr. Vamsi Krishna Potluri (Executive Director) and Mr. Trilok Potluri (Non-Executive Director) also serve on the board
  • Regulatory Confirmation: Received confirmation that Mr. Potluri is not debarred from accessing capital markets or restrained from holding director office by SEBI or any other authority

Subsidiary Loan Approval

  • Borrower: SMS Peptides Private Limited (Subsidiary Company)
  • Lender: SMS Pharmaceuticals Limited
  • Loan Amount: Up to ₹50 Crores in one or more tranches
  • Loan Type: Unsecured loan
  • Current Outstanding: Nil as of disclosure date
  • Approval Required: Subject to shareholder approval pursuant to Section 185 of Companies Act, 2013
  • Relationship: SMS Pharmaceuticals holds 99.99% stake in SMS Peptides Private Limited
  • Nature of Transaction: Related party transaction conducted at arm's length basis
  • Agreement Timing: Loan agreement will be executed subsequent to shareholder approval

Subsidiary and Associate Company Performance

  • SMS Peptides Private Limited (Subsidiary): Revenue ₹Nil lakhs, Net Loss ₹2.00 lakhs, Total Comprehensive Loss ₹2.00 lakhs for Q1 FY27
  • VKT Pharma Private Limited (Associate, 34.83% holding): Revenue ₹4,692.61 lakhs, Net Profit ₹203.31 lakhs, Total Comprehensive Income ₹206.11 lakhs for Q1 FY27
  • SMS CoLab Private Limited (Wholly owned Subsidiary): Revenue ₹Nil lakhs, Net Loss ₹0.15 lakhs, Total Comprehensive Income ₹0.15 lakhs for Q1 FY27
  • Chemo SMS Enterprises SL (Joint Venture): No operations during the quarter